The 20 Best Diffuse Midline Glioma H3 K27M-Mutant Doctors Near Me in Baltimore, MD

Eric Raabe, M.D., Ph.D., is an associate professor of oncology and pathology at Johns Hopkins School of Medicine. Dr. Raabe majored in neural science at Brown University and received his M.D. and Ph.D. from the University of Cincinnati College of Medicine. He completed his pediatric internship and residency at Children’s Hospital of Philadelphia. After spending a year working in Africa as part of the Baylor International Pediatric AIDS Initiative, Dr. Raabe joined Johns Hopkins as a pediatric oncology fellow. Working in the laboratory of Charles Eberhart in Neuropathology, Dr. Raabe established a neural stem cell system to create genetically accurate models of pediatric brain tumors. In collaboration with patients and families, he has also developed multiple pediatric brain tumor cell lines that are some of the key models used for pre-clinical testing. Dr. Raabe sees patients in the pediatric oncology outpatient clinic at Johns Hopkins, with a focus on pediatric brain tumors. Dr. Raabe is also the point person in oncology for retinoblastoma care. He continues his research in the new Smith Building of the Wilmer Eye Institute in the Neuropathology Division, in collaboration with Charles Eberhart. Dr. Raabe is rated as an Elite provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Diffuse Midline Glioma H3 K27M-Mutant, Glioma, and Medulloblastoma. Dr. Raabe is board certified in American Board Of Pediatrics.

Dr. Cohen is Director of Pediatric Neuro-Oncology and Clinical Director of the Division of Pediatric Oncology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. He received his undergraduate degree at Brown University and earned his MD at the Upstate Medical University, in Syracuse, NY. He did his general Pediatric Residency and Chief Residency at the University of Colorado and completed his Pediatric Hematology/Oncology Fellowship at Johns Hopkins. He has served on the faculty since 1994. His research centers on clinical trials of novel therapeutics for children with brain tumors. Dr. Cohen is co-chair of the High-Grade Glioma committee for the Children's Oncology Group and in that capacity has a particular research interest in the development of therapeutics for the treatment of infiltrating gliomas. He serves on the scientific advisory board for a number of organizations including St. Baldricks and the Childhood Brain Tumor Foundation. He is on the editorial board for PDQ with responsibility for authorship of the pediatric CNS brain tumor summaries. The Pediatric Neuro-Oncology program conducts a broad range of research centered primarily around the development and testing of novel therapeutics for children with brain tumors. The multidisciplinary nature of this work translates into continual collaboration with specialists in pediatric neurosurgery, radiation oncology, neuropathology, neuroradiology, neurology, neuro-ophthalmology, neuropsychology, and other related disciplines. Dr. Cohen is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Glioma, Medulloblastoma, Brain Stem Cancer, Embryonal Tumor with Multilayered Rosettes, and Bone Marrow Aspiration. Dr. Cohen is board certified in American Board Of Pediatrics.

Robyn Gartrell, MD, MS is a physician-scientist and pediatric oncologist who joined the faculty at Johns Hopkins University School of Medicine as Assistant Professor in January 2024. Dr. Gartrell completed her clinical pediatric hematology/oncology fellowship at New York Presbyterian / Columbia University Irving Medical Center (CUIMC), and a postdoctoral fellowship in Immunotherapy and Precision Medicine. She also completed a Master of Science in Patient Oriented Research as well as her first 5 years as faculty at CUIMC. Dr. Gartrell’s primary research focuses on combination approaches including radiation, chemotherapy, and other target agents with immunotherapy to improve response, increase survival, and decrease toxicity for children, adolescents, and young adults with cancer. Her laboratory uses advances in tumor immunology to develop more effective and more personalized therapies using multiplex platforms and immunogenomics to evaluate the tumor microenvironment and determine which pediatric tumor types, and which patients, will respond to immunotherapy. Dr. Gartrell is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 3 other conditions, according to our data. Her clinical expertise encompasses Glioma, Diffuse Midline Glioma H3 K27M-Mutant, HER2 Negative Breast Cancer, and Pancreatic Ductal Adenocarcinoma. Dr. Gartrell is board certified in American Board Of Pediatrics.

Dr. Jaishri Blakeley is the Marjorie Bloomberg Tiven Professor of Neurofibromatosis in Neurology, Oncology, and Neurosurgery at Johns Hopkins School of Medicine, director of the Johns Hopkins Comprehensive Neurofibromatosis Center and director of the Neurofibromatosis Therapeutic Acceleration Program (NTAP). She is an active clinician-scientist specializing in the care of people with NF1, NF2, LZTR1, SMARC1 schwannomatoses, and primary brain tumors. Her research expertise in the development of clinical trials for nervous system tumors and specifically, early clinical-translational studies including tumor pharmacokinetic and pharmacodynamic investigations, imaging biomarkers for rare nervous system tumors, and incorporation of patient-focused, functional endpoints into efficacy studies. She has been the national or international leader of 7 clinical trials focused on therapies for glioblastoma, NF1 and NF2. In 2012 she cofounded the NTAP to dramatically shift the landscape of NF1 via necessary, efficient, and expert discovery, translational and clinical research. NTAP focuses on therapeutics, fosters collaboration, facilitates open and timely sharing of results, and streamlines the research process to accelerate therapies for plexiform and cutaneous neurofibromas. Through NTAP, Dr. Blakeley has supported and collaborated with more than 80 laboratories and research teams across the globe enabling meaningful therapeutic development for NF1-associated neoplasms and supporting the development of an exceptional community of clinician scientists focused on NF1 via the Francis S. Collins Scholars Program in Neurofibromatosis Clinical and Translational Research. Her research and programmatic efforts are all in the service of improving outcomes for the patients with NF1, NF2, schwannomatosis, and primary brain cancer for whom she is honored to provide care. Dr. Blakeley is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 24 other conditions, according to our data. Her clinical expertise encompasses Neurofibromatosis, Schwannomatosis, Neurofibromatosis Type 2 (NF2), Neurofibromatosis Type 1 (NF1), and Laminectomy. Dr. Blakeley is board certified in American Board Of Psychiatry And Neurology.

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 34 other conditions, according to our data. Her clinical expertise encompasses Brain Tumor, Chordoma, Astrocytoma, and Bone Tumor. Dr. Redmond is board certified in American Board Of Radiology.

Dr. Jon Weingart focuses on the surgical treatment of brain tumors including benign and malignant tumors. Dr. Weingart also specializes in spinal disorders, such as cervical and lumbar disc disease, as well as other congenital and developmental abnormalities such as tethered spinal cord, spina bifida and chiari malformation. Dr. Weingart is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 36 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, Awake Craniotomy, and Osteotomy. Dr. Weingart is board certified in American Board Of Neurological Surgery.

Carlos Romo, M.D., is a neuro-oncologist in Baltimore, Maryland. Dr. Romo specializes in the diagnosis and treatment of brain tumors, including glioblastoma, astrocytomas, oligodendrogliomas, neurofibromas, and schwannomas among others. Dr. Romo earned his medical degree from the School of Medicine and Health Sciences at Tecnológico de Monterrey in Mexico and completed his Neurology residency at the University of Arkansas for Medical Sciences, where he served as chief resident. He then completed a Neuro-oncology clinical and research fellowship in a joint program between The Johns Hopkins University and the National Institutes of Health. Dr. Romo additionally trained as a clinical pharmacology fellow at The Johns Hopkins University and completed training on clinical cancer research at the University of Texas MD Anderson Cancer Center. In his research, Dr. Romo studies drug pharmacokinetics and the blood-brain barrier, and investigates better ways to reach tumors in the central nervous system. Dr. Romo also studies treatments for patient with neurofibromatosis. In addition to patient care and research, Dr. Romo teaches and mentors medical and undergraduate students to help develop a future generation of neurologists. Dr. Romo is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Neurofibromatosis Type 1 (NF1), Schwannomatosis, and Astrocytoma. Dr. Romo is board certified in American Board Of Psychiatry And Neurology.

Sahaja Acharya is the Director of Pediatric Radiation Oncology within the Department of Radiation Oncology and Molecular Radiation Sciences. She specializes in pediatric brain tumors, pediatric sarcomas, and adult sarcomas. She is also the Associate Director for the Radiation Oncology Residency Program. She leads the Pediatric Radiation Oncology program at the Johns Hopkins Hospital and treats patients at both Johns Hopkins Hospital and Sibley Memorial Hospital. She has extensive expertise in proton therapy, SBRT, pediatric malignancies, and adult sarcoma. She is the Principal Investigator on external grants from ASCO Conquer Cancer, the Department of Defense, and the Carson Leslie Foundation. She is also the Principal Investigator of phase II pediatric brain tumor clinical trials. She has been invited to participate in multiple national and international guideline committees and regularly lectures on pediatric malignancies and proton therapy. Dr. Acharya received her Bachelor's in Chemistry and Political Science from Stanford University and her medical degree from Saint Louis University. She completed radiation oncology residency at Washington University in St. Louis. Dr. Acharya is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 4 other conditions, according to our data. Her clinical expertise encompasses Brain Tumor, Posterior Fossa Tumor, Glioma, and Gliomatosis Cerebri. Dr. Acharya is board certified in American Board Of Radiology.

Sarah Mcavoy is a Radiation Oncologist practicing medicine in Columbia, Maryland. Dr. Mcavoy is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. She is also highly rated in 6 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Metastatic Brain Tumor. Dr. Mcavoy is board certified in American Board Of Radiology.

Dr. Koldobskiy is an Assistant Professor of Pediatric Oncology and Pediatric Neuro-Oncology at the Sidney Kimmel Comprehensive Cancer Center. He received his B.S. and M.S. from Yale University and M.D./Ph.D. in the Medical Scientist Training Program at Johns Hopkins, conducting his thesis research with Dr. Solomon Snyder in Pharmacology and Molecular Sciences. He completed his Pediatrics residency training at Johns Hopkins and his Pediatric Hematology and Oncology fellowship training in the joint Johns Hopkins/National Institutes of Health program. He studies epigenetic variability in childhood cancer. Dr. Koldobskiy is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. His clinical expertise encompasses Leukemia, Glioma, Teratoma of the Mediastinum, and Acute Lymphoblastic Leukemia (ALL). Dr. Koldobskiy is board certified in American Board Of Pediatrics.

Arpit Chhabra is a Radiation Oncologist practicing medicine in Baltimore, Maryland. Dr. Chhabra is rated as an Advanced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 54 other conditions, according to our data. His clinical expertise encompasses Pineoblastoma, Nasopharyngeal Carcinoma, Medulloblastoma, and Olfactory Neuroblastoma.

John S. Myseros, MD, is a senior pediatric neurosurgeon who joined Children’s National in 2004 and has been in practice since 1997. He has clinical and surgical expertise in and published manuscripts and textbook chapters on practically every aspect of pediatric neurosurgery, including tumors of the brain and spinal cord, craniofacial and tethered cord surgery, and vascular neurosurgery. Dr. Myseros has vast experience in and a national and international reputation and referral for brain tumors in children. He plays a vital and collaborative role in the world-class Brain Tumor Institute at Children's National. As part of the dynamic, cutting-edge and world-renowned Division of Neurosurgery, Dr. Myseros is a professor of Neurosurgery and Pediatrics and the vice chief of the division. He sees patients at the main hospital in Washington, D.C., as well the neurosurgical office in Fairfax, VA. Publications Google Scholar PUBMED. Dr. Myseros is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Craniosynostosis, Chiari Malformation, Chiari Malformation Type 1, Posterior Fossa Decompression, and Osteotomy. Dr. Myseros is board certified in Neurological Surgery: American Board Of Neurological Surgery, 2000 and American Board Of Pediatric Neurological Surgery, 2000.

Graeme Woodworth is a Neurosurgery provider practicing medicine in Baltimore, Maryland. Dr. Woodworth is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 24 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Brain Tumor, Awake Craniotomy, and Gastrostomy.

John Heiss is a Neurosurgery provider practicing medicine in Bethesda, Maryland. Dr. Heiss is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Chiari Malformation Type 2, Syringomyelia, Chiari Malformation, Laminectomy, and Posterior Fossa Decompression.

Paul Meltzer is a Hematologist and an Oncologist practicing medicine in Bethesda, Maryland. Dr. Meltzer is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Rhabdomyosarcoma, and Pancreaticoduodenectomy.

Kevin Camphausen is a Radiation Oncologist practicing medicine in Bethesda, Maryland. Dr. Camphausen is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 5 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Gliomatosis Cerebri.

John Laterra is a Neurologist practicing medicine in Baltimore, Maryland. Dr. Laterra is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Haroon Ahmad is a Neurologist practicing medicine in Baltimore, Maryland. Dr. Ahmad is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Oligodendroglioma, Glioma, Astrocytoma, and Glioblastoma.

Samir Kanani is a Radiation Oncologist practicing medicine in Silver Spring, Maryland. Dr. Kanani is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Prostate Cancer, Familial Prostate Cancer, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET).

Mohamed Labib is a Neurosurgery provider practicing medicine in Baltimore, Maryland. Dr. Labib is rated as an Experienced provider by MediFind in the treatment of Diffuse Midline Glioma H3 K27M-Mutant. He is also highly rated in 4 other conditions, according to our data. His clinical expertise encompasses Brain Stem Cancer, Radiation Induced Meningioma, Dysembryoplastic Neuroepithelial Tumors (DNET), Extracranial-Intracranial Bypass Surgery, and Cerebral Artery Bypass Surgery.